Karyopharm Therapeutics | KPTI - Selling And Administration Expenses


Karyopharm Therapeutics reported $9.56M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Abbott USD 3.13B 125M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Takeda JPY 282.78B 29.23B Dec/2025
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025